Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16121142 | 0.80 | MAPT (0.38) | MAPTPOLBHTTSMN1; SMN2CYP1A2 | |
| SCHEMBL19274937 | 0.69 | ALDH1A1 (0.56) | MAPTPOLBSMN1; SMN2 | |
| SCHEMBL16126885 | 0.69 | — | — | |
| SCHEMBL14818802 | 0.68 | ADORA2A (0.33) | — | |
| SCHEMBL16126887 | 0.66 | PI4KA (0.30) | — | |
| SCHEMBL21467540 | 0.64 | — | — | |
| SCHEMBL19155825 | 0.63 | COMT (0.32) | — | |
| SCHEMBL33843 | 0.62 | — | — | |
| SCHEMBL691349 | 0.61 | — | — | |
| Hydrochloric Acid SCHEMBL7115195 | 0.61 | PI4KA (0.38) | POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434763-B2 | Derivatives of pyridinone as inhibitors for tissue transglutaminase | ZEDIRA GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9242937-B2 | Pharmaceutically active disubstituted pyridine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEADDISCOVERY CENTER GMBH (DE) | 2015-11-19 | — | — | US | disclosed |
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | ZEDIRA GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-20140296304-A1 | Pharmaceutically Active Disubstituted Pyridine Derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | PLPBP, PNPO, PDXK | MAPT 1682/4885POLB 2106/4885HTT 3407/4885 |
| US-20140296304-A1 | Pharmaceutically Active Disubstituted Pyridine Derivatives | PINK1, PDPK1, LCK | MAPT 1370/4885POLB 2367/4885HTT 2441/4885 |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | MAPT 3310/4885POLB 1828/4885HTT 4630/4885 |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | AXL, FLT3, ERBB3 | MAPT 2425/4885POLB 4518/4885HTT 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.